BR0214383A - Tratamento de hipertonia durante a fase aguda do ataque de apoplexia - Google Patents

Tratamento de hipertonia durante a fase aguda do ataque de apoplexia

Info

Publication number
BR0214383A
BR0214383A BR0214383-6A BR0214383A BR0214383A BR 0214383 A BR0214383 A BR 0214383A BR 0214383 A BR0214383 A BR 0214383A BR 0214383 A BR0214383 A BR 0214383A
Authority
BR
Brazil
Prior art keywords
treatment
stroke
acute phase
hypertonia
during
Prior art date
Application number
BR0214383-6A
Other languages
English (en)
Inventor
Joachim Schrader
Original Assignee
Solvay Pharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Gmbh filed Critical Solvay Pharm Gmbh
Publication of BR0214383A publication Critical patent/BR0214383A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"TRATAMENTO DE HIPERTONIA DURANTE A FASE AGUDA DO ATAQUE DE APOPLEXIA". A invenção refere-se ao uso de uma substância para inibição do sistema de renina-angiotensina no tratamento do ataque agudo de apoplexia.
BR0214383-6A 2001-11-23 2002-11-25 Tratamento de hipertonia durante a fase aguda do ataque de apoplexia BR0214383A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10157474 2001-11-23
DE10158030 2001-11-27
PCT/EP2002/013238 WO2003043615A2 (de) 2001-11-23 2002-11-25 Hypertoniebehandlung während der akuten phase des schlaganfalls

Publications (1)

Publication Number Publication Date
BR0214383A true BR0214383A (pt) 2004-11-03

Family

ID=26010631

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0214383-6A BR0214383A (pt) 2001-11-23 2002-11-25 Tratamento de hipertonia durante a fase aguda do ataque de apoplexia

Country Status (9)

Country Link
US (1) US20050009893A1 (pt)
EP (1) EP1450793A2 (pt)
JP (1) JP2005511631A (pt)
AU (1) AU2002364381A1 (pt)
BR (1) BR0214383A (pt)
CA (1) CA2467095A1 (pt)
MX (1) MXPA04004844A (pt)
PL (1) PL370270A1 (pt)
WO (1) WO2003043615A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
PL353199A1 (en) * 1999-08-30 2003-11-03 Aventis Pharma Deutschland Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
WO2012024657A1 (en) 2010-08-20 2012-02-23 IntegenX, Inc. Microfluidic devices with mechanically-sealed diaphragm valves
US8633158B1 (en) 2012-10-02 2014-01-21 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions
US9333233B2 (en) * 2014-02-25 2016-05-10 Tarix Pharmaceuticals Ltd. Methods and compositions for the delayed treatment of stroke

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4010797A1 (de) * 1990-04-04 1991-10-10 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung
CA2048699A1 (en) * 1990-09-04 1992-03-05 Abraham Sudilovsky Method for preventing or treating cerebro-vascular disease employing ceronapril
US20010018448A1 (en) * 1990-12-14 2001-08-30 Smithkline Beecham P.L.C. Medicament
GB9027199D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
US6162802A (en) * 1992-03-10 2000-12-19 Papa; Joseph Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor
AU726694B2 (en) * 1996-03-29 2000-11-16 Smithkline Beecham Corporation Eprosartan dihydrate and a process for its production and formulation
AU742506B2 (en) * 1997-10-17 2002-01-03 Eurogene Limited The use of inhibitors of the renin-angiotensin system
CA2332608C (en) * 1998-06-17 2010-03-23 Bristol-Myers Squibb Company Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination
FR2783422A1 (fr) * 1998-09-21 2000-03-24 Sanofi Sa Composition pharmaceutique contenant un antagoniste des recepteurs at1 de l'angiotensine ii et un antiagregant plaquettaire
WO2001005428A1 (en) * 1999-07-21 2001-01-25 Takeda Chemical Industries, Ltd. Preventives for the recurrence of cerebrovascular failure and agents for ameliorating troubles following cerebrovascular failure and inhibiting progress thereof
PL353199A1 (en) * 1999-08-30 2003-11-03 Aventis Pharma Deutschland Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
AU2001242184A1 (en) * 2000-03-28 2001-10-08 Queen:S University At Kingston Methods for effecting neuroprotection using a potassium channel modulator
RU2298418C2 (ru) * 2000-04-12 2007-05-10 Новартис Аг Комбинация по меньшей мере двух соединений, выбранных из групп антагонистов at1-рецептора или ингибиторов асе (ангиотензинпревращающий фермент), или ингибиторов hmg-coa-редуктазы (бета-гидрокси-бета-метилглутарил-кофермент-а-редуктаза)
HUP0302455A3 (en) * 2000-12-18 2005-05-30 Novartis Ag Combination pharmaceutical compositions containing amplodipine and benazepril and their use
DE10115668A1 (de) * 2001-03-29 2002-10-10 Max Delbrueck Centrum Mittel zur Behandlung des Schlaganfalls

Also Published As

Publication number Publication date
AU2002364381A1 (en) 2003-06-10
MXPA04004844A (es) 2004-07-30
WO2003043615A3 (de) 2004-02-19
PL370270A1 (en) 2005-05-16
JP2005511631A (ja) 2005-04-28
CA2467095A1 (en) 2003-05-30
US20050009893A1 (en) 2005-01-13
WO2003043615A2 (de) 2003-05-30
EP1450793A2 (de) 2004-09-01

Similar Documents

Publication Publication Date Title
FR2811552B1 (fr) Composition notamment cosmetique ou pharmaceutique se presentant sous forme solide
DK0956858T3 (da) Farmaceutiske præparater indeholdende lactobacilli til behandling af vaginale infektioner
IL196301A0 (en) Medicament for the treatment of hapatitis c
IS6560A (is) Lyfjasamsetning fyrir meðhöndlun á bráðum, þrálátum sársauka og/eða taugakerfissársauka og mígreni
DK2412368T3 (da) Sammensætning til behandling af ar
DE60100143D1 (de) Freisetzungssystem von Cyclopropenderivaten, welches eine kleinere Wassermenge benützt
BR0213358A (pt) Uso de flibanserina
DE60019158D1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
BR0106287B1 (pt) seringa de segurança.
DK1282616T3 (da) Hydroxyphenylpiperidin-4-ylidenmethylbenzamidderivater til behandling af smerter
BR0107667A (pt) Composto de linezolida em forma de cristal que e farmaceuticamente útil como agente antibacteriano e método de preparação do mesmo
BRPI0110506B8 (pt) uso de inibidores de il-18 para o tratamento e/ou prevenção da aterosclerose
PT1206436E (pt) Retinoides para o tratamento de enfisema
IT1313007B1 (it) Processso per l'alchilazione di composti aromatici in fase gas.
DE60037258D1 (de) System zur verwaltung des endpunktschlages
DE50108168D1 (de) Transdermales therapeutisches system zur abgabe von lerisetron
BR0214383A (pt) Tratamento de hipertonia durante a fase aguda do ataque de apoplexia
EE200300213A (et) SARP-1 kasutamine sklerodermia raviks ja/või ennetamiseks
PT1220858E (pt) Oxazinoquinolonas uteis para o tratamento de infeccoes virais
PT1273556E (pt) Estacao de tratamento simbiotico de aguas residuais.
BR0313230A (pt) Uso de carboxamidas para o tratamento de tinido
IT1319940B1 (it) Dispositivo per favorire l'unificazione costruttiva di cartucce perapparecchi idraulici.
ATE299704T1 (de) Warmgeformte feste arzneizusammensetzung zur gesteuerten wirkstoffabgabe von perindopril
AU2001291604A1 (en) Use of proton pump inhibitors for treating diseases of the locomotor system
ES1053064Y (es) Dispositivo para la preparacion de un producto tal como hormigon o mortero.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2064 DE 27/07/2010.